Australia's largest stock trading and investment forum Australia's #1 stock forum

MDC

Click for more information

0.00%

$6.60 medlab clinical limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-29

First 29 Last

Share
Profile

Follow
Deb_R

161 Posts.

27

04/11/22

06:44

Post #: 64581067
Share

Originally posted by Apse: ↑

- NanaBis is completely built on the NanoCelle delivery platform, which is the key differentiator over every other cannabinoid product or company seeking regulatory approvals globally.

- Validating NanoCelle through an FDA approved drug (NanaBis) literally *is* their core business and a major way they will generate huge concrete revenues through immediate sales and lock down big pharma partnerships on NanoCelle.

- Based on precedents such as GW Pharma's Epidiolex, or even Sativex (which I suspect was the drug NanaBis has already blown out of the water in independent testing) an FDA approval will be immensely profitable (~US$500m+ YR1 sales).

If anything, by divesting the VMS business, cutting costs and locking down funds through a Nasdaq listing, Medlab seem to be extremely focussed on their core business objectives.

Expand

how much nanabis has been sold through SAS scheme?

MDC Price at posting: $10.00 Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Banking on ANZ in this week's Hot Stock tips

INA

Ingenia shares jump 7% on strong revenue and earnings figures

UNT

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

USL

'Joaquin Silver District' acquisition to become a key asset for Unico

There are more pages in this discussion • 27 more messages in this thread...

First 29 Last

Add MDC (ASX) to my watchlist

SPONSORED BY